Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
BAALC was identified by gene expression studies in patients with acute myeloid leukemia (AML). Additionally we are shipping BAALC Antibodies (42) and BAALC Kits (4) and many more products for this protein.
Showing 8 out of 9 products:
Human BAALC Protein expressed in Escherichia coli (E. coli) - ABIN668049
Tanner, Austin, Leone, Rush, Plass, Heinonen, Mrózek, Sill, Knuutila, Kolitz, Archer, Caligiuri, Bloomfield, de La Chapelle: BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemia. in Proceedings of the National Academy of Sciences of the United States of America 2001
Show all 2 references for ABIN668049
BAALC and ERG (show ERG Proteins) genes are specific significant molecular markers in acute myeloid leukemia (show BCL11A Proteins) disease progression, response to treatment and survival.
demonstrated that BAALC blocks ERK (show EPHB2 Proteins)-mediated monocytic differentiation of acute myeloid leukemia (show BCL11A Proteins) cells by trapping Kruppel-like factor 4 (KLF4 (show KLF4 Proteins)) in the cytoplasm and inhibiting its function in the nucleus
combined determination of both miR (show MLXIP Proteins)-3151 and BAALC improved this prognostic stratification, with patients with low levels of both parameters showing a better outcome compared with those patients harboring increased levels of one or both markers
study indicates that overexpression of BAALC serves as an independent prognostic biomarker in acute myeloid leukemia (show BCL11A Proteins)
Evaluating WT1 (show WT1 Proteins) and BAALC gene expression at diagnosis may improve standard risk stratification and possibly refine the therapeutic approach for Myelodysplastic Syndromes patients.
Thus low MDR1/low BAALC expression identifies a subgroup of intermediate cytogenetic risk AML (show RUNX1 Proteins) patients with a remarkably good long-term outcome achieved by chemotherapy alone.
miR (show MLXIP Proteins)-3151 introns within BAALC have roles in driving leukemogenesis by deregulating the TP53 (show TP53 Proteins) pathway
Higher BAALC expression and FLT3 (show FLT3 Proteins)-ITD mutation, both individually and in combination, were associated with worse survival outcomes in CN-AML (show RUNX1 Proteins), and this was also applicable in NPM1 (show NPM1 Proteins)-mutated CN-AML (show RUNX1 Proteins), known as a favorable-risk group.
BAALC overexpression retains its negative prognostic role across all cytogenetic risk groups in acute myeloid leukemia (show BCL11A Proteins) patients.
higher post-HSCT BAALC and WT1 (show WT1 Proteins) expressions in patients with CBF-AML (show RUNX1 Proteins) may be good markers of minimal residual disease for the prediction of survival and relapse after HSCT.
BAALC/Baalc is a marker of the mesodermal lineage, especially muscle.
This gene was identified by gene expression studies in patients with acute myeloid leukemia (AML). The gene is conserved among mammals and is not found in lower organisms. Tissues that express this gene develop from the neuroectoderm. Multiple alternatively spliced transcript variants that encode different proteins have been described for this gene\; however, some of the transcript variants are found only in AML cell lines.
brain and acute leukemia cytoplasmic protein
, brain and acute leukemia, cytoplasmic